Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04693195 · ClinicalTrials.gov registry record · Phase 2
A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis and Chronic Pruritus, sponsored by Bellus Health Inc. - a GSK company.
- Completed
- Registry status
- Phase 2
- Development phase
- 142
- Enrollment target
- 20
- Study locations
NCT04693195: Completed Phase 2 study of Atopic Dermatitis and Chronic Pruritus, sponsored by Bellus Health Inc. - a GSK company.
NCT04693195 is a Phase 2 study of Atopic Dermatitis and Chronic Pruritus that has completed, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 142 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04693195, a Phase 2 study of Atopic Dermatitis and Chronic Pruritus, has completed, sponsored by Bellus Health Inc. - a GSK company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 142 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter, randomized, double-blind, placebo-controlled, parallel design study of BLU-5937 for the treatment of chronic pruritus in adult subjects with atopic dermatitis (AD).
Primary Outcome
Assessed by Worst Itch Numeric Rating Scale \[WI-NRS\] The WI-NRS is a single item questionnaire assessing the patient-reported severity of itch at its most intense during the previous 24-hour period on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'the worst itch imaginable'. Higher scores indicate worse severity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BLU-5937
Study Locations (20)
Florida
- Bellus Health Investigational Site #15 - Hialeah
- Bellus Health Investigational Site #32 - Margate
- Bellus Health Investigational Site #16 - Miami
- Bellus Health Investigational Site #19 - Miami
- Bellus Health Investigational Site #17 - Sweetwater
California
- Bellus Health Investigational Site #23 - Beverly Hills
- Bellus Health Investigational Site #33 - Encinitas
- Bellus Health Investigational Site #27 - Fountain Valley
- Bellus Health Investigational Site #35 - San Diego
Louisiana
- Bellus Health Investigational Site #38 - Baton Rouge
- Bellus Health Investigational Site #45 - Covington
- Bellus Health Investigational Site #18 - New Orleans
Arizona
- Bellus Health Investigational Site #28 - Phoenix
- Bellus Health Investigational Site #10 - Scottsdale
Georgia
- Bellus Health Investigational Site #24 - Savannah
Kentucky
- Bellus Health Investigational Site #13 - Owensboro
Minnesota
- Bellus Health Investigational Site #36 - Minneapolis
New Hampshire
- Bellus Health Investigational Site #22 - Portsmouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2020-12-09 |
| Est. Completion | 2021-10-12 |
| Phase | Phase 2 |
What the finished NCT04693195 record still lists
NCT04693195 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04693195 names 20 study sites across 10 states, led by Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT04693195 about?
NCT04693195 is a clinical study titled "A Multiple-Dose Study of BLU-5937 in Chronic Pruritus Associated With Atopic Dermatitis". This is a multicenter, randomized, double-blind, placebo-controlled, parallel design study of BLU-5937 for the treatment of chronic pruritus in adult subjects with atopic dermatitis (AD).
What is the current status of trial NCT04693195?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 142 participants. The study started on 2020-12-09. Estimated completion is 2021-10-12.
What conditions does trial NCT04693195 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Chronic Pruritus.
What interventions are being tested in trial NCT04693195?
The interventions under investigation include: Placebo (DRUG), BLU-5937 (DRUG).
Who is sponsoring clinical trial NCT04693195?
This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04693195 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04693195's enrollment target sits among peer trials
142 74th of 150 higher than 77 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI